Continuing Medical EdUcation (CME)


The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.


AACR has designated this live activity for a maximum of 25.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.


Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey (link below) by Wednesday, November 9, 2016. Certificates will only be issued to those who complete the survey.  Your CME certificate will be sent to you via email after the completion of the activity.


According to American Cancer Society, in 2016, there will be an estimated 1,658,370 new cancer cases and 595,690 people will die from the disease. Almost 40% of men and women will be diagnosed with cancer during their lifetimes. While surgery, chemotherapy and radiotherapy have been the mainstay of cancer treatments, these have significant side effects and are often ineffective. Novel, safe and tolerable therapeutic approaches are greatly needed.

New technologies have greatly enhanced our understanding of immune surveillance, vastly contributing to the development of novel immunotherapies. To further improve the prognosis and outcome of subsequent therapies, it is extremely important to understand the interaction of tumor cells with their micro-environment.

To develop more effective therapies for a broader range of cancer types, it is essential to provide a venue for researchers, physician scientists, and all stakeholders, to meet, share novel findings, and have an active exchange of ideas.  This conference, which is the only international event of its kind in the immunotherapy space, will focus on recent advances in cancer immunology and immunotherapy, which includes areas such as:  immune regulation of T cell responsiveness, genomic methods for identifying tumor antigens, the tumor microenvironment, T cell therapies, checkpoint blockade, adaptive immunity, adoptive T-cell therapies, biomarkers, imaging, combination therapies, viral infections and vaccination, and the microbiome. The potential of immune-based therapeutics will be fully explored and successes in clinical trials and clinical trial design will be discussed. 

After participating in this CME activity, physicians should be able to:

  • Assess the contribution of tumor microenvironment and microbiome in tumor progression and growth.
  • Evaluate genomic methods for identifying tumor antigens.
  • Identify mechanisms involved in the biology of vaccination.
  • Articulate how checkpoint blockade is being used in a therapeutic setting.  
  • Articulate how recent advances are contributing to personalized cancer immunotherapy.
  • Describe the principles of cancer immunotherapy, the value of combination therapy, and mechanisms of new immunotherapy drugs. 


It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.


This activity is supported by grants and will be disclosed at the activity. 


Please contact the Office of CME at (215) 440-9300 or